Related Experiment Video
Updated: Sep 16, 2025

Adsorption Device Based on a Langatate Crystal Microbalance for High Temperature High Pressure Gas Adsorption in Zeolite H-ZSM-5
Published on: August 25, 2016
The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis
Steven Fishbane1, Laura M Dember2, Michel Jadoul3
1Division of Nephrology, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
Insights
Sodium zirconium cyclosilicate (SZC) did not reduce cardiovascular events in hemodialysis patients with hyperkalemia, despite effectively controlling serum potassium levels. Further research is needed to clarify its role in managing kidney disease complications.
Area of Science:
- Nephrology
- Cardiology
- Clinical Trials
Background:
- Maintenance hemodialysis patients often have predialysis hyperkalemia, increasing arrhythmia and cardiovascular risks.
- The DIALIZE-Outcomes trial investigated sodium zirconium cyclosilicate (SZC) for these outcomes.
Purpose of the Study:
- To evaluate the efficacy of sodium zirconium cyclosilicate (SZC) in reducing arrhythmia-related cardiovascular events in hemodialysis patients.
- To assess SZC's effect on serum potassium control and overall cardiovascular safety.
Main Methods:
- Adult hemodialysis patients with hyperkalemia (serum potassium ≥5.5 mmol/l) were randomized to SZC or placebo.
- The primary endpoint was a composite of sudden cardiac death, stroke, or arrhythmia-related hospitalizations/interventions.
- SZC dosage was titrated weekly to achieve normokalemia (4.0-5.0 mmol/l).
Main Results:
- The trial was terminated early due to low event rates and high discontinuation.
- SZC showed no significant effect on the primary composite cardiovascular endpoint (HR 0.98; 95% CI 0.76-1.26).
- SZC significantly improved normokalemia maintenance (74.0% vs. 47.0%; OR 3.36) but had higher rates of hypokalemia (3.0% vs. 1.4%).
Conclusions:
- Sodium zirconium cyclosilicate (SZC) did not demonstrate a benefit for arrhythmia-related cardiovascular outcomes in this population.
- Despite its efficacy in serum potassium normalization, SZC's clinical utility for preventing major cardiovascular events remains unproven.
Introduction:
Patients receiving maintenance hemodialysis frequently experience predialysis hyperkalemia, with associated arrhythmias and cardiovascular events. The DIALIZE-Outcomes trial evaluated the effect of sodium zirconium cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes.
Methods:
Adults receiving thrice-weekly hemodialysis with predialysis hyperkalemia (serum potassium was 5.5 mmol/l or more) were randomized 1:1 to SZC (5 g once daily on nondialysis days, then titrated weekly over 4 weeks between 0 and 15 grams to attain normokalemia [serum potassium 4.0-5.0 mmol/l]) or placebo. The primary outcome was a composite end point of sudden cardiac death, stroke, or arrhythmia-related hospitalization, intervention, or emergency department visit. Secondary end points included individual cardiovascular outcomes from the primary composite end point, and those reflecting serum potassium control. Safety was evaluated throughout.
Results:
Overall, 2690 participants were randomized. The trial was terminated early due to low event rates (∼33% of planned) and high study medication discontinuation rates, limiting generalizability of the results. No treatment effect was observed on the primary composite end point (SZC, 8.8% [119 patients] vs. placebo, 8.9% [119 patients]; hazard ratio 0.98; 95% confidence interval 0.76-1.26) or individual cardiovascular outcomes. Maintenance of normokalemia at 12 months was significantly better with SZC than placebo (74.0% [495 patients] vs. 47.0% [293 patients]; odds ratio 3.36; 95% confidence interval 2.64-4.26). Serious adverse events occurred in 38.6% (SZC) and 37.6% (placebo) of participants; hypokalemia occurred in 3.0% (SZC) and 1.4% (placebo).
Conclusions:
SZC did not demonstrate a treatment effect on arrhythmia-related cardiovascular outcomes despite efficacy on serum potassium control.
Trial Registration:
Registered at ClinicalTrials.gov with study number NCT04847232.
More Related Videos
07:13High Temperature Fabrication of Nanostructured Yttria-Stabilized-Zirconia YSZ Scaffolds by In Situ Carbon Templating Xerogels
Published on: April 16, 2017
11:14Two-way Valorization of Blast Furnace Slag: Synthesis of Precipitated Calcium Carbonate and Zeolitic Heavy Metal Adsorbent
Published on: February 21, 2017
Related Concept Videos
Hemodialysis II: Procedure and Complications
Dialysis
Hemodialysis I: Introduction
Hemodialysis III: Nursing Management
Continuous Renal Replacement Therapy
Acute Kidney Injury V: Interprofessional Care